Annual Results Year to 31 March 2019 AGM, November 2019 1
Financial summary: underlying performance to 31 March 2019 £000 6,000 35.0% 5,000 30.0% 4,000 25.0% 3,000 20.0% 2,000 15.0% 1,000 10.0% 0 5.0% 2015 2016 2017 2018 2019 2019 Actual Run rate -1,000 0.0% 7m of Medimark 12m of Medimark Trading Income One-offs EBITDA One-offs as % of total revenue Byotrol plc estimates: smoothed net income from Solvay deal 2018/1019, non-recurring costs included as costs 2
Byotrol plc: Technologies Traditional Technologies Newly Developed Technologies Technology HLD4 BYOTROL 24 ACTIZONE* HOCL HAND SANITISER Platforms Surface care for EU Surface care for US Surface care for EU Sporicidal surface care Alcohol-free hand sanitisers BPR and MDD EPA BPR for EU BPR and MDD for EU under BPR Seaweed – anti virals Surface care & QFS Market HEALTHCARE OTHER PROF. CONSUMER Segments Animal Healthcare Food Retail Jansan Incl petcare Human Healthcare BPR - Biocides Products Regulation (EU) MDD – Medical Device Directive (EU) Relevant Regulatory Agency EPA – Environmental Protection Agency (US) * In alliance with Solvay 3
Byotrol plc: US surface care • US EPA-approved, long-lasting germ kill surface cleaner/sanitiser. Unique claims for US consumer market. US$1bn addressable market. • Target ‘trial’ in 207 stores across US remains underway; no discrete end date, but progress is under regular review… and sales increasing despite minimal marketing spend • Extensive consumer research now completed by Nielsen. Confirms strength of proposition: 79% Agree – A 24-hour surface sanitizer is a good idea and I would use it in my home. o 78% Agree – I trust Byotrol24 would keep my surfaces sanitized for 24 hours. o 64% Agree – I think Byotrol24 would work better than the current all-purpose cleaner I use. o • Now seeking financial or corporate partner to accelerate growth. Sales $'s TY vs. LY $2,000 $1,500 $1,000 $500 $ This Year 2019 Last Year2018 4
Byotrol plc: outlook • Progressing with plan • Technology-led sales in Professional markets – especially animal health, human health - and in Consumer • EU Surface care via Medimark products and Solvay(Actizone) • US surface care: product proposition established; now seeking partner to accelerate growth • Expansion of alcohol-free hand sanitisers launched into healthcare – direct and white label • Integrating Medimark • Strategic planning mode at present – identifying synergies including: costs, rationalising technologies, monetisation strategies for non core technologies • Execution post completion of earnout on 31 March 2020 • Still very well-positioned for long-term growth • Visible, sustainable profits in sight from trading income only • Monetisation opportunities for legacy technologies and new technologies • Strong balance sheet • Strong leadership team • Positive market dynamics – growing market, regulations biting, consolidation underway 5
Recommend
More recommend
